XU
XUP.STU Genfit SA
- Market cap
- EUR 540M
- P/E
- -
- P/B
- 3.35x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is XUP.STU undervalued?
Graham numberThe Graham number of Genfit SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genfit SA fundamental analysis
No fundamental analysis for Genfit SA yet.
Genfit SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genfit SA
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemi…
Full company profileGenfit SA financial statements
Genfit SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 284K | 118K | 7.36M | 30.8M | 765K | 80.1M | 20.2M | 28.6M | 67.0M | 65.4M |
| Gross Profit | -1.70M | -2.11M | 5.51M | - | 563K | 80.1M | 19.9M | 28.2M | 66.7M | 65.1M |
| Operating Income | -34.2M | -56.7M | -69.5M | -57.8M | -77.6M | 32.0M | -27.3M | -27.2M | 3.23M | -53.6M |
| EBITDA | - | -55.3M | -67.1M | -51.0M | -72.8M | 79.3M | -17.2M | -22.2M | 8.32M | -83.5M |
| Net Income | -33.7M | -58.6M | -79.5M | -65.1M | -101M | 67.3M | -23.7M | -28.9M | 1.51M | -86.0M |
| EPS | - | -1.88 | -2.55 | -1.68 | -2.61 | 1.35 | -0.48 | -0.58 | 0.03 | -1.72 |
| Balance Sheet | ||||||||||
| Total Assets | 166M | 293M | 229M | 310M | 199M | 282M | 216M | 174M | 151M | 159M |
| Total Liabilities | 23.4M | 189M | 209M | 226M | 215M | 163M | 121M | 106M | 82.2M | 182M |
| Shareholders' Equity | 143M | 104M | 20.9M | 84.1M | -16.2M | 119M | 94.5M | 68.0M | 69.2M | -22.5M |
| Cash & Short-term Investments | 152M | 274M | 207M | 277M | 171M | 259M | 136M | 77.8M | 81.8M | 101M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -27.2M | -49.9M | -56.1M | -47.7M | -96.4M | 99.9M | -72.6M | -55.4M | 15.5M | -26.2M |
| Capital Expenditure | 2.04M | 2.80M | 2.94M | 2.03M | 900K | 537K | 0.00 | 2.49M | 979K | 3.42M |
| Free Cash Flow | - | -52.7M | -59.0M | -49.7M | -97.3M | 99.4M | -72.6M | -57.9M | 14.6M | -29.7M |
| Ratios | ||||||||||
| ROE | -23.6% | -56.2% | -379.8% | -77.5% | - | 56.5% | -25.1% | -42.5% | 2.2% | - |
| ROA | -20.3% | -20.0% | -34.7% | -21.0% | -51.0% | 23.9% | -11.0% | -16.6% | 1.0% | -54.1% |
| Net Profit Margin | -11,854.6% | -49,664.4% | -1,079.9% | -211.2% | -13,231.5% | 84.0% | -117.4% | -101.2% | 2.2% | -131.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genfit SA dividends
Genfit SA has not paid dividends in the last 10 fiscal years.
Who owns Genfit SA
- Insiders 13.22%
- Institutions 14.26%
- Public & others 72.52%
- Shares outstanding 50.0M
- Free float 41.1M
Genfit SA company profile
- Company name
- Genfit SA
- Ticker
- XUP.STU
- ISIN
- FR0004163111
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 169
- Fiscal year end
- December
- Address
- Parc Eurasanté, Loos, France, 59120
- Phone
- 33 3 20 16 40 00
- Website
- genfit.com
About Genfit SA
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Genfit SA management
10- Mr. Jean-Francois MouneyCo-Founder & Chairman of the Board · born 1955
- Mr. M. Pascal PrigentChief Executive Officer · born 1968
- Mr. John BrozekExecutive VP of Data & Information Technology and Director · born 1977
- Prof. Bart StaelsCo-Founder & Chairman of the Scientific Advisory Board · born 1963
- Mr. Thomas BaetzChief Financial Officer · born 1974
- Mr. Pascal CaiseyDeputy CEO & COO · born 1968
- Ms. Sakina Sayah-JeanneChief Scientific Officer · born 1972
- Mr. Jean-Christophe MarcouxChief Corporate Affairs Officer, Head of Investor Relations & Head of ESG · born 1977
- Mr. Laurent LannooCorporate Secretary & Director of Legal Affairs · born 1970
- Ms. Stefanie Magner J.D.Chief Compliance Officer & Executive VP of International Legal Affairs · born 1981